Cytomed Therapeutics Limited · NASDAQ:GDTC
Cytomed Therapeutics — Investor Presentation (May 2023)
24 slides from Cytomed Therapeutics's investor presentation, May 2023
Slide 1: CytoMed Therapeutics Limited Investor Presentation
CytoMed Therapeutics Limited NASDAQ: GDTC Investor Presentation May 2023 www.cytomed.sg
Slide 2: Important Notice
Important Notice Forward-Looking Statements This Presentation and the accompanying oral presentation contain] “forward-looking statements” that are based on our beliefs and assumptions and on information currently available to us, and include, without limitation, statements regarding our business, f
Slide 3: Cancer Therapies with Broad Applications
Cancer Therapies with Broad Applications Mission: Engineering more affordable cellular cancer therapies to identify and attack a broad- spectrum of solid & blood cancers. 3
Slide 4: CytoMed Therapeutics Limited
Headquartered and incorporated in Singapore, CytoMed Therapeutics was spun out from A*STAR, Singapore’s Agency for Science, Technology and Research, in March of 2018. CytoMed Therapeutics Limited (NASDAQ: GDTC) The biopharmaceutical company is focused on harnessing its licensed proprietary technolog
Slide 5: Experienced Leadership
Experienced Leadership Chairman and Director Mr. Peter CHOO Chee Kong has over 20 years of experience in corporate finance, strategy, and corporate governance, is well-versed in company IPOs, and has served as director on several SGX listed companies. Director and Chief Clinical Officer Dr. Lucas LU
Slide 6: Key Takeaways
Key Takeaways 1 2 3 4 5 Healthy donor- Potentially Potentially derived, High barriers to Potential for scalable, off-the- reduced risk of allogeneic-use entry growth shelf products secondary therapies for with low capital cancers and broad spectrum costs adverse effects of solid and blood cancers 6
Slide 7: Potential to Treat Numerous Types of Cancer
Potential to Treat Numerous Types of Cancer NKG2D CAR recognises eight NKG2D ligands, which are expressed on a wide range of cancers. Sample list of NKG2D ligands expressed in human cancers Tumor type Ligands Identified Tumor type Ligands Identified Acute Lymphoblastic Leukemia 28-67% MICA/B Hepatoc
Slide 8: Massive Addressable Market Opportunity
Massive Addressable Market Opportunity Total Addressable Market Cancer patients, globally Service Addressable Market Patients who fail at least two frontline treatments (chemo; surgery; radiation; etc.) Service Obtainable Market Southeast Asia; large and relevant initial market with future expansion
Slide 9: Three Therapies Targeting Solid & Blood Cancers
Three Therapies Targeting Solid & Blood Cancers Therapeutic Cell Products • γδ T cells (CTM-GDT) • CAR-γδ T cells (CTM-N2D) • iPSC-γδ NKT cells (iPSC-gdNKT) Each cell type naturally expresses an array of built-in receptors to recognize cancers. Starting Materials • Donor blood cells • iPSCs (induced
Slide 10: Asset #1 | CAR-γδ T Cell Therapy
Asset #1 | CAR-γδ T Cell Therapy Chimeric Antigen Receptor Gamma Delta T Cells Begin Phase 1 Submitted Singapore’s Trial CTM-N2D Phase 1 trial application Jul 2020 Dec 2021 Jan 2023 2H 2023 Successfully Health Sciences manufactured Authority granted novel CTM-N2D first-in-human therapy Ph. 1 clinica
Slide 11: Asset #1 | Building on CAR-T Technology
Asset #1 | Building on CAR-T Technology Chimeric Antigen Receptors (CAR) can specifically recognize and will only bind to ligands. Upon CAR-ligand binding, signals are sent into the immune cell activating it to kill the target. CAR Introduction CAR-T Therapy Introduction Target Ligand A CAR A Target
Slide 12: Asset #1 | CytoMed's Streamlined Manufacturing
Asset #1 | CytoMed’s Streamlined Manufacturing • Potentially guaranteed cell • Potentially no risk numbers of secondary • Reasonable cell cancers quality • Potentially no risk • Potentially no of long-term Simple blood draw Healthy donor Mononuclear cell γδ T cell mRNA adverse effects contamination
Slide 13: Asset #2 | Unmodified γδ T Cell Therapy
Asset #2 | Unmodified γδ T Cell Therapy Unmodified Gamma Delta T Cells Preparing Drug Clinical Trial Master File for Application U.S. Research Malaysia Initiative Feb 2021 After 2023 Successfully translated γδ T cell expansion technology into a clinical grade product CTM-GDT 13
Slide 14: Asset #2 | Unmodified γδ T Manufacturing
Asset #2 | Unmodified γδ T Manufacturing CTM-GDT consists of expanded allogeneic gamma delta T cells and exploits the inherent potential of these cells to recognize and treat a broad range of cancers. 14
Slide 15: Asset #3 | iPSC-γδ NKT Cell Therapy
Asset #3 | iPSC-γδ NKT Cell Therapy Novel Gamma Delta Natural Killer T Cells Generated from Induced Pluripotent Stem Cells Pre-clinical process development Completed the proof-of- concept studies May 2019 Jun 2022 2023 Japanese patent for iPSC-gdNKT technology granted to Accelerate Technologies Pte.
Slide 16: Asset #3 | What is iPSC?
Asset #3 | What is iPSC? To move away from blood donor dependency, we believe iPSC is significantly more efficient as a starting material to produce immune cells. iPSC engineered in the lab is similar to embryonic stem cells iPSCs provide unlimited starting material to generate various therapeutic c
Slide 17: Asset #3 | iPSC-γδ NKT Manufacturing
Asset #3 | iPSC-γδ NKT Manufacturing Integrating cancer recognition capabilities of both gamma delta T cells and natural killer cells into γδ NKT cells to potentially generate one potent therapeutic product. 17
Slide 18: Asset #3 Seek, see and destroy ‒ γδ NKT
Asset #3 Seek, see and destroy ‒ γδ NKT cells in action! 18
Slide 19: Patent-Pending Intellectual Property
Patent-Pending Intellectual Property Two key patent-pending IPs (exclusively licensed from A*STAR), supporting three allogeneic + “off-the-shelf” + broad Patent-pending Patent-pending spectrum cancer target platforms. IP#1: IP#2: Both include manufacturing CAR-γδ T Cell iPSC-derived γδ NKT process,
Slide 20: Path to Commercialization
Path to Commercialization We believe this offering will facilitate our efforts to demonstrate safety before raising additional capital. IPO Proceeds 20
Slide 21: Regulatory Progress
Regulatory Progress CTA application was acknowledged and approved by the Health Sciences Authority, Singapore in January for Phase I ANGELICA clinical trial (NCT05302037) to be conducted with the National University Hospital Singapore CTM-N2D Therapy Approvals Manufacturing Standards ✓ Health Scienc
Slide 22: Financial Highlights
Financial Highlights Year Ended December 31, 2020 and 2021 Six Months Ended June 30, 2021 and 2022 Financial Highlights Financial Highlights Income Statement 2020 2021 Change Income Statement 2021 2022 Change US$ US$ % US$ US$ % Revenue - - - Revenue - - - Other Operating Income1 91,675 111,206 21.3
Slide 23: Use of Proceeds
Use of Proceeds Approximately: advancing clinical development of CTM-N2D through Phase I 21.5% and up to the stage of commencing Phase II clinical trial 21.5% technological developments of iPSC-gdNKT advancing clinical development of CTM-GDT for Phase I 10.7% clinical trial in Malaysia funding other
Slide 24: Investment Summary
Investment Summary • Three allogeneic, broad-spectrum cancer targeting cell-based therapies • Applications for both solid and blood cancers • Potentially scalable, off-the-shelf products • Clear strategy for commercialization, to target conditional marketing of products post Phase II clinical trial
CytoMed Therapeutics — Investor Presentation (May 2023) on 6ix